Big Beat for Gilead on Rising Sovaldi Revenue

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)

Have Markets Peaked?: What'd You Miss? (Full Show 04/29)
27:36 - Full episode of "What'd You Miss?" Guests include: Ben Laidler, HSBC Securities global equity strategist, Chris White, Viablemkts chief executive officer, and Meredith Sumpter, Eurasia Group Asia director. (Source: Bloomberg)
  • The Week in Tech From Bloomberg West (04/29)
  • Has Apple's Hot Streak Come to an End?
  • NBC Puts Olympics Video on Snapchat